Erik Bjornson serves as Vice President, Regulatory Affairs at Hemab. He brings more than 25 years of experience in the pharmaceutical industry with a focus on the development of products for rare bleeding disorders. He started his career at Baxter Healthcare and has been involved with the development and licensure of numerous products, including ADVATE, ADYNOVATE, VONVENDI, RIXUBIS and OBIZUR. Erik’s experience includes roles at Baxter Healthcare, Baxalta, Shire, Takeda and most recently Galderma, where he was the Head of Biologics Regulatory Strategy. He earned his Bachelor of Science in Chemistry from Texas Christian University, Fort Worth.